BRIEF-Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease
February 08, 2017 at 18:37 PM EST
* Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease